Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 11

1.

Immuno-PET of Murine T Cell Reconstitution Postadoptive Stem Cell Transplantation Using Anti-CD4 and Anti-CD8 Cys-Diabodies.

Tavaré R, McCracken MN, Zettlitz KA, Salazar FB, Olafsen T, Witte ON, Wu AM.

J Nucl Med. 2015 Aug;56(8):1258-64. doi: 10.2967/jnumed.114.153338. Epub 2015 May 7.

2.

Immunotherapy in Cancer: A Combat between Tumors and the Immune System; You Win Some, You Lose Some.

Madorsky Rowdo FP, Baron A, Urrutia M, Mordoh J.

Front Immunol. 2015 Mar 26;6:127. doi: 10.3389/fimmu.2015.00127. eCollection 2015. Review.

3.

Immune Checkpoint Blockade in Cancer Therapy.

Postow MA, Callahan MK, Wolchok JD.

J Clin Oncol. 2015 Jun 10;33(17):1974-82. doi: 10.1200/JCO.2014.59.4358. Epub 2015 Jan 20. Review.

4.

PET imaging to non-invasively study immune activation leading to antitumor responses with a 4-1BB agonistic antibody.

Escuin-Ordinas H, Elliott MW, Atefi M, Lee M, Ng C, Wei L, Comin-Anduix B, Montecino-Rodriguez E, Avramis E, Radu C, Sharp LL, Ribas A.

J Immunother Cancer. 2013 Aug 27;1:14. doi: 10.1186/2051-1426-1-14. eCollection 2013.

5.

FLT PET-CT in evaluation of treatment response.

Sanghera B, Wong WL, Sonoda LI, Beynon G, Makris A, Woolf D, Ardeshna K.

Indian J Nucl Med. 2014 Apr;29(2):65-73. doi: 10.4103/0972-3919.130274. Review.

6.

CTLA4 blockade broadens the peripheral T-cell receptor repertoire.

Robert L, Tsoi J, Wang X, Emerson R, Homet B, Chodon T, Mok S, Huang RR, Cochran AJ, Comin-Anduix B, Koya RC, Graeber TG, Robins H, Ribas A.

Clin Cancer Res. 2014 May 1;20(9):2424-32. doi: 10.1158/1078-0432.CCR-13-2648. Epub 2014 Feb 28. Erratum in: Clin Cancer Res. 2015 Jul 15;21(14):3359.

7.

Engineered antibody fragments for immuno-PET imaging of endogenous CD8+ T cells in vivo.

Tavaré R, McCracken MN, Zettlitz KA, Knowles SM, Salazar FB, Olafsen T, Witte ON, Wu AM.

Proc Natl Acad Sci U S A. 2014 Jan 21;111(3):1108-13. doi: 10.1073/pnas.1316922111. Epub 2014 Jan 3.

8.

Biomarkers on melanoma patient T cells associated with ipilimumab treatment.

Wang W, Yu D, Sarnaik AA, Yu B, Hall M, Morelli D, Zhang Y, Zhao X, Weber JS.

J Transl Med. 2012 Jul 12;10:146. doi: 10.1186/1479-5876-10-146.

9.

Melanoma vaccines and modulation of the immune system in the clinical setting: building from new realities.

Madorsky-Rowdo FP, Lacreu ML, Mordoh J.

Front Immunol. 2012 May 4;3:103. doi: 10.3389/fimmu.2012.00103. eCollection 2012.

10.

CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans.

Huang RR, Jalil J, Economou JS, Chmielowski B, Koya RC, Mok S, Sazegar H, Seja E, Villanueva A, Gomez-Navarro J, Glaspy JA, Cochran AJ, Ribas A.

Clin Cancer Res. 2011 Jun 15;17(12):4101-9. doi: 10.1158/1078-0432.CCR-11-0407. Epub 2011 May 10.

11.

Development of radiotracers for oncology--the interface with pharmacology.

Sharma R, Aboagye E.

Br J Pharmacol. 2011 Aug;163(8):1565-85. doi: 10.1111/j.1476-5381.2010.01160.x. Review.

Supplemental Content

Support Center